[Human pharmacokinetics of AR-L 115 BS (author's transl)].
Following i.v. administration of 0.7 mg of 2-[(2-methoxy-4-methylsulfinyl)phenyl]-1H-imidazo[4,5-b]pyridine (AR-L 115 BS)/kg (bolus) the terminal plasma elimination half-life (beta-phase) was in the range of 50 min. A fast absorption of the patent compound could be observed after oral administration of 50, 75, 10 and 150 mg AR-L 115 BS (solution). The AR-L 115 BS plasma level behaviour was characterised by a fast elimination of the parent compound.
D000284:Administration, Oral; D000328:Adult; D002316:Cardiotonic Agents / Q000008:administration & dosage / Q000378:metabolism*; D004032:Diet; D006801:Humans; D007093:Imidazoles / Q000008:administration & dosage / Q000378:metabolism*; D007275:Injections, Intravenous; D007700:Kinetics; D008297:Male; D008875:Middle Aged; D011485:Protein Binding
D002316:Cardiotonic Agents; D007093:Imidazoles; C029758:sulmazole
Zur Humanpharmakokinetik von AR-L 115 BS.